drugset / Trial / NCT02659085

Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder

NCT02659085

Phase 2/3 Completed 198 enrolled Pouya Movahed Rad
RandomizedParallel-groupOpen-labelTreatment

Summary

Developing more effective and faster acting antidepressant is of outmost clinical importance. Available antidepressant therapies have a delayed therapeutic effect. It typically takes several weeks before symptom relief is evident. Furthermore, antidepressants are relatively ineffective - as many as 30% of patients do not respond to any medication at all. In this study the investigators evaluate the NMDA-receptor antagonist ketamine as a potentially new antidepressant treatment for severely depressed patients and compare its effectiveness with that of electroconvulsive therapy (ECT).

Timeline

Start
2015-02
Primary completion
2019-08
Completion
2019-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous